the best experience when you visit . by using this website you consent to our use of these cookies . find out more about how we use cookies and how to manage them by reading our cookie notice . close search menu search search search close what science can do what science can do our people our science our science pipeline publications cambridge gothenburg gaithersburg imed biotech unit medimmune global medicines developement our focus areas cardiovascular and metabolic diseases oncology respiratory inflammation and autoimmunity neuroscience infection and vaccines all focus areas all medicines our company our company our strategy leadership team careers careers global careers site investors investor relations results and presentations key facts for investors faqs corporate governance dividend policy regulatory announcements partnering partnering partnering case studies get in touch media media centre image library broadcast videos sustainability sustainability environmental sustainability access to healthcare ethical business practices responsible research great place to work governance more hide az network global site media centre media centre image library broadcast videos more media centre contact the global media team see below for contact details see below for contact details contact the global media team all contacts neil burrows head of global media relations 44 203 749 5637 vanessa rhodes director global media relations 44 203 749 5736 karen birmingham director global science media 44 203 749 5634 rob skelding global media relations director 44 203 749 5821 jacob lund director external communications sweden 46 8 553 260 20 lotta sj sten manager media relations sweden 46 8 553 271 10 us media team load all contacts press releases and articles all all corporate and financial partnering science sustainability refine results items 608 refine your results content type corporate press release article video regulatory announcement therapy area cardiovascular and metabolic diseases oncology respiratory inflammation and autoimmunity neuroscience gastrointestinal infection and vaccines research centre gaithersburg us gothenburg sweden cambridge uk other locations reset filters apply 7 october 2016 astrazeneca enters agreement with cilag gmbh international to divest rights to rhinocort aqua outside the us corporate press release 4 october 2016 astrazeneca enters agreement with aralez for beta blocker medicine toprol xl in the us corporate press release 4 october 2016 astrazeneca reports top line results from the brilinta euclid trial in patients with peripheral artery disease corporate press release 3 october 2016 medimmune out licenses potential medicine for inflammatory diseases to allergan corporate press release 30 september 2016 astrazeneca presents new data on faslodex in breast cancer and provides immuno oncology update at esmo 2016 congress corporate press release 28 september 2016 professor david goldstein to lead astrazeneca s genomics initiative as chief adviser 28 september 2016 astrazeneca appoints david goldstein as chief adviser for its genomics initiative 23 september 2016 innovative pancreatic research expands treatment horizons for people with type 2 diabetes 22 september 2016 liquid biopsy plasma ctdna testing moves into mainstream cancer treatment 21 september 2016 astrazeneca provides update on cediranib eu marketing authorisation application corporate press release 20 september 2016 patients at the core of partnership 20 september 2016 peripheral patients pad peripheral arterial disease policy initiative 20 september 2016 can drag and drop cancer simulation speed up drug discovery 16 september 2016 phase iii combination trial of bydureon and forxiga shows significant benefits in patients with type 2 diabetes corporate press release 15 september 2016 opening up a treasure trove of new drug target opportunities 14 september 2016 astrazeneca recognised as a leader in 2016 dow jones sustainability indices djsi 12 september 2016 astrazeneca announces two new phase iiib trials for forxiga in chronic kidney disease and chronic heart failure corporate press release 8 september 2016 pepfar and astrazeneca launch partnership across hiv and hypertension services in africa 5 september 2016 benralizumab phase iii trials show positive results in severe asthma corporate press release 1 september 2016 astrazeneca completes commercialisation agreement with aspen for anaesthetics portfolio corporate press release 30 august 2016 astrazeneca to present new data highlighting its growing respiratory portfolio and pipeline at european respiratory society 2016 corporate press release 24 august 2016 astrazeneca to sell small molecule antibiotics business to pfizer corporate press release 22 august 2016 astrazeneca and lilly receive fda fast track designation for azd3293 an investigational treatment for early alzheimer s disease corporate press release 19 august 2016 breakthrough research revealing novel drivers of cardiometabolic diseases published in science 16 august 2016 uncovering world s first structural clues to inhibiting an emerging dna damage response target area for future anti cancer therapy 9 august 2016 astrazeneca provides update on phase iii trial of selumetinib in non small cell lung cancer corporate press release 28 july 2016 h1 2016 results corporate press release 26 july 2016 astrazeneca files first clinical trial application in moderna messenger rna collaboration 21 july 2016 astrazeneca s antibiotic zavicefta met primary endpoints in phase iii trial for treatment of hospital acquired pneumonia corporate press release 19 july 2016 astrazeneca receives approval in the eu for qtern saxagliptin and dapagliflozin for treatment of type 2 diabetes corporate press release 18 july 2016 tagrisso met primary endpoint in phase iii 2nd line lung cancer trial corporate press release 1 july 2016 astrazeneca enters licensing agreements with leo pharma in skin diseases corporate press release 28 june 2016 new antibiotic zavicefta approved in the european union for patients with serious bacterial infections corporate press release 23 june 2016 astrazeneca provides update on flumist quadrivalent vaccine in the us for the 2016 17 influenza season corporate press release 9 june 2016 astrazeneca enters commercialisation agreement with aspen for anaesthetic medicines portfolio corporate press release 4 june 2016 astrazeneca and foundation medicine enter strategic collaboration for lynparza companion diagnostic assay corporate press release 3 june 2016 astrazeneca completes us licensing agreement with ironwood pharmaceuticals for lesinurad corporate press release 3 june 2016 new study published in cancer cell furthers understanding role of cxcr2 in pancreatic cancer 2 june 2016 astrazeneca licenses zurampic to gr nenthal gmbh in europe and latin america corporate press release 27 may 2016 astrazeneca s faslodex met primary endpoint in first line treatment of advanced breast cancer corporate press release 27 may 2016 positive chmp opinion in eu for saxa dapa saxagliptin and dapagliflozin for adults with type 2 diabetes corporate press release 27 may 2016 clinical trial data unveil a driver of fgfr inhibitor response in gastric cancer 27 may 2016 astrazeneca receives complete response letter from us fda for sodium zirconium cyclosilicate zs 9 for oral suspension for treatment of hyperkalaemia corporate press release 19 may 2016 astrazeneca highlights continued progress of oncology pipeline at 2016 asco annual meeting corporate press release 18 may 2016 astrazeneca provides top line results from lynparza gold trial in advanced gastric cancer corporate press release 17 may 2016 astrazeneca announces positive results from benralizumab phase iii programme in severe asthma corporate press release 16 may 2016 defining a new approach to developing nanomedicines for cancer therapies 12 may 2016 selumetinib granted orphan drug designation in the us for adjuvant treatment of differentiated thyroid cancer corporate press release 12 may 2016 astrazeneca to highlight the breadth of its respiratory medicines at american thoracic society 2016 international conference corporate press release 12 may 2016 astrazeneca commissions new report on global stroke burden 9 may 2016 astrazeneca joins life science leaders to support uk s continued membership of the eu 9 may 2016 astrazeneca and lieber institute for brain development publish discovery of novel protein associated with schizophrenia 6 may 2016 astrazeneca supports world ovarian cancer day 2016 3 may 2016 astrazeneca completes divestment of imdur to china medical system holdings corporate press release 3 may 2016 astrazeneca completes acquisition of takeda s respiratory business corporate press release 29 april 2016 q1 2016 results corporate press release 29 april 2016 positive chmp opinion for caz avi in the eu for serious bacterial infections corporate press release 26 april 2016 new genomic classification approach strengthens early cancer trial design 26 april 2016 astrazeneca enters into us licensing agreement with ironwood pharmaceuticals for lesinurad corporate press release 25 april 2016 new studies published in nature immunology further understanding of immune system 22 april 2016 astrazeneca launches integrated genomics approach to transform drug discovery and development corporate press release 14 april 2016 astrazeneca showcases breadth of oncology portfolio at aacr 2016 annual meeting corporate press release 8 april 2016 astrazeneca and eli lilly and company announce continuation of pivotal clinical trial for people with early alzheimer s disease corporate press release 6 april 2016 astrazeneca to showcase clinical and scientific leadership in lung cancer at elcc 2016 corporate press release 1 april 2016 pandemic influenza vaccine receives positive chmp opinion corporate press release 31 march 2016 brilinta preferred over clopidogrel in updated american college of cardiology and american heart association guideline in acute coronary syndrome corporate press release 29 march 2016 tagrisso osimertinib approved in japan for patients with egfr t790m mutation positive metastatic non small cell lung cancer corporate press release 23 march 2016 astrazeneca reports top line results from the brilinta socrates trial in stroke corporate press release 9 march 2016 astrazeneca s potential medicine for neuromyelitis optica receives fda orphan drug designation corporate press release 7 march 2016 medimmune receives fast track designation in the us for medi8852 for treatment of patients hospitalised with influenza a corporate press release 1 march 2016 astrazeneca enters into agreement with prostrakan for rights to moventig in europe corporate press release 29 february 2016 astrazeneca enters licensing agreement with china medical system holdings for hypertension medicine corporate press release 29 february 2016 astrazeneca reports top line result of tremelimumab monotherapy trial in mesothelioma corporate press release 25 february 2016 acalabrutinib recommended for orphan drug designation in europe for three indications corporate press release 19 february 2016 zurampic lesinurad approved in the european union for patients with gout corporate press release 19 february 2016 brilique ticagrelor approved in eu for extended treatment of patients with history of heart attack corporate press release 17 february 2016 durvalumab granted breakthrough therapy designation by us fda for treatment of patients with pd l1 positive urothelial bladder cancer corporate press release 11 february 2016 astrazeneca and medimmune enter consortium to deliver new treatments for chronic kidney disease corporate press release 11 february 2016 astrazeneca and bind therapeutics publish azd2811 accurins data in science translational medicine 4 february 2016 full year and q4 2015 results corporate press release 3 february 2016 tagrisso osimertinib approved in eu as first in class treatment for patients with egfr t790m mutation positive metastatic non small cell lung cancer corporate press release 2 february 2016 astrazeneca completes transaction for majority equity stake investment in acerta pharma corporate press release 28 january 2016 lynparza olaparib granted breakthrough therapy designation by us fda for treatment of brca1 2 or atm gene mutated metastatic castration resistant prostate cancer corporate press release 25 january 2016 astrazeneca partners with peers and academia to establish translational research fund corporate press release 21 january 2016 working together to beat the rising threat of drug resistant infections 13 january 2016 unveiling of s cience in pictures at the cambridge biomedical campus 11 january 2016 astrazeneca and incyte announce new lung cancer clinical trial collaboration corporate press release 11 january 2016 astrazeneca and moderna therapeutics announce new collaboration to co develop and co commercialise immuno oncology mrna therapeutics corporate press release 22 december 2015 zurampic lesinurad approved by us fda for patients with gout corporate press release 18 december 2015 brilique ticagrelor receives positive european union chmp opinion for extended treatment of patients with a history of heart attack corporate press release 18 december 2015 tagrisso osimertinib receives positive chmp opinion for patients with egfr t790m mutation positive metastatic non small cell lung cancer corporate press release 18 december 2015 chmp issues positive opinion on lesinurad for gout corporate press release 18 december 2015 durvalumab atlantic trial supports clinical activity and astrazeneca s overall immuno oncology strategy corporate press release 17 december 2015 astrazeneca completes acquisition of zs pharma